Brown, Lisle/Cummings’s AstraZeneca AZN Stock Holding History

Brown, Lisle/Cummings’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$122K	Buy	617 +156	+34%	+$30.1K	0.03%	268
2025 Q4	$84.8K	Sell	461 -75	-14%	-$13.2K	0.02%	299
2025 Q3	$82.2K	Hold	536	–	–	0.02%	297
2025 Q2	$74.9K	Hold	536	–	–	0.02%	298
2025 Q1	$78.7K	Buy	536 +43	+9%	+$6.22K	0.02%	293
2024 Q4	$64.6K	Buy	493 +39	+9%	+$5.46K	0.02%	302
2024 Q3	$70.7K	Hold	454	–	–	0.02%	291
2024 Q2	$70.8K	Hold	454	–	–	0.02%	280
2024 Q1	$61.5K	Hold	454	–	–	0.02%	275
2023 Q4	$61.2K	Hold	454	–	–	0.02%	271
2023 Q3	$61.5K	Hold	454	–	–	0.03%	253
2023 Q2	$65K	Hold	454	–	–	0.03%	259
2023 Q1	$63K	Buy	454 +79	+21%	+$10.6K	0.03%	257
2022 Q4	$50.8K	Buy	375 +16	+4%	+$2.01K	0.03%	264
2022 Q3	$39.4K	Hold	359	–	–	0.02%	274
2022 Q2	$47.4K	Buy	359 +15	+4%	+$1.97K	0.03%	265
2022 Q1	$45.6K	Buy	344 +44	+15%	+$5.28K	0.02%	272
2021 Q4	$35K	Buy	+300	New	+$35.3K	0.02%	301

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Brown, Lisle/Cummings's AZN Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its AstraZeneca (AZN) stake by 34% in Q1 2026, buying an estimated $30.1K and bringing the position to 617 shares worth $122K. The position accounts for 0.03% of the portfolio, ranked #268.

Brown, Lisle/Cummings first reported a position in AZN in Q4 2021 and has held it in 18 quarters since. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Brown, Lisle/Cummings held 617 shares of AstraZeneca worth $122K as of Q1 2026.
Brown, Lisle/Cummings bought 156 AstraZeneca shares in Q1 2026, an estimated $30.1K.
AstraZeneca made up 0.03% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #268 holding.
Brown, Lisle/Cummings first reported a position in AstraZeneca in Q4 2021 and has held it in 18 quarters since.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.